Program leads to remission of Type 2 diabetes with a reduction in average hemoglobin A1c of 1.5% combined with average Total Body Weight Loss of 16.2% after just 4 months

Allurion Technologies, a company dedicated to ending obesity, today announced new clinical data on the Allurion Program as an emerging novel treatment for Type 2 diabetes and prediabetes, presented at ObesityWeek® 2021. The program, which is available across clinics in the United Arab Emirates, has been clinically proven to treat patients living with these conditions, bringing them into disease remission.

The Allurion Program is a 360-degree weight loss experience. At its center is the Allurion Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, which passes naturally after approximately 16 weeks. Furthermore, patients benefit from remote monitoring through the Allurion Virtual Care Suite which includes the Allurion Connected Scale, Health Tracker, and App, and Allurion Insights, a portal that enables message, telehealth, and end-to-end patient management.

Despite the availability of pharmacologic therapies for Type 2 diabetes, the incidence of the metabolic disease continues to rise around the world. According to the International Diabetes Federation, 537 million adults are now living with diabetes worldwide, an increase of 16% (74 million people) since 2019. And, by 2045, about 783 million people, or one in eight adults, will be living with diabetes worldwide, indicating that current treatment options are not sufficient[1]. Additionally, diabetes is not only increasing globally but at a much faster rate in regions such as the UAE, where the population with diabetes is projected to increase to about 2.2 million by 2040[2].

Dr. Shantanu Gaur, co-founder and CEO Allurion, said Allurion’s mission is to act as a catalyst to end obesity and the resulting effects from the disease, including diabetes. “Obesity and Type 2 diabetes are pandemics of unprecedented magnitude, and they often afflict patients simultaneously,” Gaur said. “Current treatments for obesity and diabetes either suffer from poor safety and efficacy or a poor patient experience. The Allurion Program offers a compelling alternative for the treatment of both of these conditions.”

In an abstract submitted and accepted for presentation at ObesityWeek® 2021, the Allurion Gastric Balloon Program was noted as an emerging novel treatment for Type 2 diabetes and prediabetes*. The data showed that for people with diabetes, after four months, the mean haemoglobin A1c (HbA1c) decreased from 7.0% to 5.5% with a mean weight loss of 19.3kg in patients with diabetes. Remission of diabetes is typically defined as lowering HbA1c to below 6.5%, indicating that the average patient in the diabetes group achieved remission after just four months.

Dr. Ram Chuttani, co-founder and Chief Medical Officer of Allurion commented on the clinical study which included 226 patients, all of whom had been diagnosed as a Type 2 diabetic or pre-diabetic (highly likely to go on to develop type 2 diabetes in the future).

“The Allurion Program provides patients with an effective tool to reduce HbA1c and put Type 2 diabetes into remission,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “These results underscore the benefits of the Allurion Program beyond weight loss and highlight how quickly the Allurion Program can have an impact on patients with Type 2 diabetes or prediabetes.”

For more information, please visit https://allurion.com/en/find-clinic

-ENDS-